Breakthrough Clinical Data: Oraglutide Delivers Sustained Glucose Control for Six Days From a Single Oral Capsule — With No Reported Side Effects
Perspectives on Commercialisation of Oral Insulin
The Lifesciences Magazine’s New Issue Features the Most Innovative Biopharma Company Targeting Diabetes in 2024
Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
Diabetology Limited: Undertaking Groundbreaking Diabetes and Obesity R&D Solutions in Biotech
Oral Insulin – Harnessing the Natural Physiology of Glucose Control in the Body
Safety and efficacy of an oral insulin (Capsulin) in patients with early-stage type 2 diabetes: A dose-ranging phase 2b study
Oral Delivery of Biologics via the Intestine by Roger New
The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes
A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects